Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Agilent Technologies

(

A

) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.6%. By the end of trading, Agilent Technologies fell $0.66 (-1.2%) to $53.73 on average volume. Throughout the day, 2,997,086 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 2,772,500 shares. The stock ranged in price between $52.86-$54.93 after having opened the day at $54.85 as compared to the previous trading day's close of $54.39. Other companies within the Health Care sector that declined today were:

OncoGenex Pharmaceuticals

(

OGXI

), down 60.3%,

Transition Therapeutics

(

TTHI

), down 12.3%,

POZEN

(

POZN

), down 10.4% and

Arrowhead Research

(

ARWR

), down 9.8%.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $18.4 billion and is part of the health services industry. The company has a P/E ratio of 26.2, above the S&P 500 P/E ratio of 17.7. Shares are down 4.9% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Agilent Technologies

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front,

Furiex Pharmaceuticals

TheStreet Recommends

(

FURX

), up 28.6%,

Agenus

(

AGEN

), up 19.5%,

ProPhase Labs

(

PRPH

), up 13.1% and

AstraZeneca

(

AZN

), up 12.2% , were all gainers within the health care sector with

Johnson & Johnson

(

JNJ

) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.